-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Peking University Health Science Center and others have jointly launched the Chinese Pan-cancer Early Screening and Early Diagnosis Cohort Research Project, covering more than 20 kinds of cancers in China, including lung cancer, colorectal cancer, gastric cancer, etc.
, of which 15 cancers currently have no clear and effective screening methods
in international or domestic clinical guidelines.
, of which 15 cancers currently have no clear and effective screening methods
in international or domestic clinical guidelines.
This project is the world's first breakthrough research project to screen and early diagnose multiple cancer types through the large-scale identification of plasma cell-free DNA, RNA and proteins, and is expected to be completed in stages from laboratory research to clinical application in patients
in six years 。 Simply put, this screening technology is to collect a tube of blood samples, determine the risk of more than 20 high-incidence cancers, and the accuracy is higher than the existing international early screening and early diagnosis technology, the current international leading mainstream cancer early screening and early diagnosis technology research mainly focuses on plasma cell-free DNA methylation, and the core technology is monopolized
by some international companies.
in six years 。 Simply put, this screening technology is to collect a tube of blood samples, determine the risk of more than 20 high-incidence cancers, and the accuracy is higher than the existing international early screening and early diagnosis technology, the current international leading mainstream cancer early screening and early diagnosis technology research mainly focuses on plasma cell-free DNA methylation, and the core technology is monopolized
by some international companies.
Qiao Jie, academician of the Chinese Academy of Engineering and executive vice president of Peking University: Through three-dimensional detection of DNA, RNA and proteins in the blood, we can get accurate diagnosis and treatment methods for early diagnosis and treatment of the 20 different types of tumors that we currently target, so that tumor patients can be found 1, 3 or 5 years
earlier.
For example, in patients with ovarian cancer, in fact, ultrasound finds the tumor relatively late, and even after chemotherapy and radiotherapy, the quality of life is reduced and the time of life may be shortened
.
Therefore, we especially hope that through such a pan-cancer early screening technology, we can achieve early diagnosis and early treatment, reduce the time of tumor patient discovery, and truly change the life trajectory
of tumor patients.
earlier.
For example, in patients with ovarian cancer, in fact, ultrasound finds the tumor relatively late, and even after chemotherapy and radiotherapy, the quality of life is reduced and the time of life may be shortened
.
Therefore, we especially hope that through such a pan-cancer early screening technology, we can achieve early diagnosis and early treatment, reduce the time of tumor patient discovery, and truly change the life trajectory
of tumor patients.
